Ovid Therapeutics Inc.OVIDNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank36
3Y CAGR+1.3%
5Y CAGR-16.8%
Year-over-Year Change
Research and development spending
3Y CAGR
+1.3%/yr
vs -7.6%/yr prior
5Y CAGR
-16.8%/yr
Recent acceleration
Acceleration
+8.9pp
Accelerating
Percentile
P36
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $25.58M | -30.4% |
| 2024 | $36.77M | +28.6% |
| 2023 | $28.59M | +16.1% |
| 2022 | $24.62M | -47.6% |
| 2021 | $46.94M | -26.8% |
| 2020 | $64.12M | +36.8% |
| 2019 | $46.86M | +38.7% |
| 2018 | $33.79M | -32.4% |
| 2017 | $49.97M | +421.3% |
| 2016 | $9.59M | - |